HUP9801499A2 - Pharmaceutical composition of methastasis-inhibiting activity and process for producing the composition - Google Patents
Pharmaceutical composition of methastasis-inhibiting activity and process for producing the compositionInfo
- Publication number
- HUP9801499A2 HUP9801499A2 HU9801499A HUP9801499A HUP9801499A2 HU P9801499 A2 HUP9801499 A2 HU P9801499A2 HU 9801499 A HU9801499 A HU 9801499A HU P9801499 A HUP9801499 A HU P9801499A HU P9801499 A2 HUP9801499 A2 HU P9801499A2
- Authority
- HU
- Hungary
- Prior art keywords
- composition
- methastasis
- producing
- inhibiting activity
- pharmaceutical composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract 2
- CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 abstract 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 239000001358 L(+)-tartaric acid Substances 0.000 abstract 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 abstract 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 abstract 1
- 239000002211 L-ascorbic acid Substances 0.000 abstract 1
- 235000000069 L-ascorbic acid Nutrition 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000002001 anti-metastasis Effects 0.000 abstract 1
- 229910052796 boron Inorganic materials 0.000 abstract 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract 1
- 239000010941 cobalt Substances 0.000 abstract 1
- 229910017052 cobalt Inorganic materials 0.000 abstract 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 229960001484 edetic acid Drugs 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract 1
- 229910052750 molybdenum Inorganic materials 0.000 abstract 1
- 239000011733 molybdenum Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229910052759 nickel Inorganic materials 0.000 abstract 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 abstract 1
- 229940074439 potassium sodium tartrate Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 abstract 1
- 229910052720 vanadium Inorganic materials 0.000 abstract 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An antimetastatic composition comprises one or more of the following: (a) zinc, boron, fluorine, magnesium, vanadium, manganese, iron, cobalt, nickel, copper or molybdenum containing compounds; and (b) glycine, glycerin, L-(+)-ascorbic acid, succinic acid, a neutral or acidic water-soluble salt of ethylenediamine tetra acetic acid, potassium sodium tartrate or L-(+)-tartaric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9801499A HU227305B1 (en) | 1998-07-02 | 1998-07-02 | Pharmaceutical composition of methastasis-inhibiting activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9801499A HU227305B1 (en) | 1998-07-02 | 1998-07-02 | Pharmaceutical composition of methastasis-inhibiting activity |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| HU9801499D0 HU9801499D0 (en) | 1998-09-28 |
| HUP9801499A2 true HUP9801499A2 (en) | 2000-04-28 |
| HUP9801499A3 HUP9801499A3 (en) | 2000-05-29 |
| HU227305B1 HU227305B1 (en) | 2011-03-28 |
Family
ID=89996764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9801499A HU227305B1 (en) | 1998-07-02 | 1998-07-02 | Pharmaceutical composition of methastasis-inhibiting activity |
Country Status (1)
| Country | Link |
|---|---|
| HU (1) | HU227305B1 (en) |
-
1998
- 1998-07-02 HU HU9801499A patent/HU227305B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU227305B1 (en) | 2011-03-28 |
| HUP9801499A3 (en) | 2000-05-29 |
| HU9801499D0 (en) | 1998-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL295352A1 (en) | Method of obtaining a new pharmaceutic preparation | |
| CA2326660A1 (en) | Method for producing transdermal therapeutic systems by using basic alkali metal salts for converting active agent salts into free bases | |
| CA2359116A1 (en) | Substituted porphyrins | |
| CA2342856A1 (en) | Stabilized two-part disinfecting system and compositions and methods related thereto | |
| SG170798A1 (en) | Process for synthesizing organoelemental compounds | |
| CA2356154A1 (en) | Ligands and complexes for enantioselective hydrogenation | |
| CA2224155A1 (en) | 1-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)cytosine | |
| AU2003227030A1 (en) | Process for exchanging the anions of cationic compounds | |
| CA2323906A1 (en) | Process for the preparation of bisphosphines | |
| AU5923000A (en) | Incipient wetness method for making metal-containing cyanide catalysts | |
| WO2003106011A3 (en) | A method for producing organometallic compounds | |
| GR1004211B (en) | Method for reduction of nickel | |
| GB9826540D0 (en) | Process | |
| WO2002058666A3 (en) | Process for preparing non-hygroscopic sodium valproate composition | |
| HUP9801499A2 (en) | Pharmaceutical composition of methastasis-inhibiting activity and process for producing the composition | |
| MY134966A (en) | Alkaline earth metal complexes and their use | |
| AU2001250662A1 (en) | Sequestering | |
| AU6578400A (en) | Novel method for preparing benzoperhydroisoindole compounds | |
| MX9603655A (en) | Process for the preparation of pentenalene. | |
| AU5214900A (en) | Pressed products of non-caking salt | |
| BG103651A (en) | Compounds and methods for the preparation of substituted 4-phenyl-4-cyanocyclohexanoic acids | |
| MY110796A (en) | Process for the manufacture of aminomethanephosphonic acid | |
| MX2007005170A (en) | Catalyst compositions and their use in the de-enrichment of enantiomerically enriched substrates. | |
| UA66851C2 (en) | Furylphosphines, organometallic complexes based thereon, method for the preparation thereof and catalysts | |
| AU5419699A (en) | Methoximinophenylacetic acid amides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: BERES VAGYONKEZELOE ES FEJLESZTOE KFT., HU Free format text: FORMER OWNER(S): BERES VAGYONKEZELOE ES FEJLESZTOE KFT., HU; BERES VAGYONKEZELOE ES FEJLESZTOE KFT., HU |